Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Thoracic Oncology
  •  Surgical Oncology
  •  Carcinomas
  •  Paediatric Cancers
  •  Central Nervous System Tumors
  •  Chemoprevention
  •  Leukemia
  •  Gynecological Cancers


Citation: Clin Oncol. 2022;7(1):1965.DOI: 10.25107/2474-1663.1965

Is There Re-Staging Surgery Necessity for Women with Borderline Ovarian Tumors

Guo L, Kang X, Su Y, Liu X, Wu X, Xie W, Liu H and Wang C

Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

*Correspondance to: Changyu Wang 

 PDF  Full Text Research Article | Open Access


Purpose: To assess the necessity of re-staging surgery in women with Borderline Ovarian Tumors (BOTs) and to evaluate the impact of complete surgical staging, lymphadenectomy or omentectomyon disease recurrence and survival.
Methods: We retrospectively reviewed the medical records of patients with BOTs. A total of 901 patients were eligible for the study. Some of the variables, clinical and surgical characteristics of the cases were evaluated. The effects of type of surgery procedures, surgical staging, complete or incomplete staging on prognosis were calculated. The disease-free survival, overall survival and recurrence rates were compared. COX regression analysis was employed to identify potential prognostic factors. Survival curves were constructed using Kaplan-Meier method.
Results: The overall recurrence rate was 13.9%. Recurrence rates were comparable within complete surgical staging group or incomplete groups (p>0.05). But performance complete staging surgery has not been shown to reduce long-term survival. Complete surgical staging, omentectomy and lymphadenectomy didn't cause any difference on survival. In multivariate analyses, only performance of radical surgery and adjuvant chemotherapy were risk factors for the recurrence of BOTs. Furthermore, we found that omentectomy lead to a relative lower recurrence rate in patients FIGO stage >I (p=0.022).
Conclusion: Our study suggests that complete staging surgery should be considered as a standard treatment for patients with advanced stage BOTs but not stage I. It might be safe to shrink the scope of the surgical procedures in early-stage BOT patients. There is no necessity to do restaging operations for BOT with macroscopically normal ex-ovarian appearance.


Borderline ovarian tumor; Staging surgery; Management; Recurrence

Cite the Article:

Guo L, Kang X, Su Y, Liu X, Wu X, Xie W, et al. Is There Re-Staging Surgery Necessity for Women with Borderline Ovarian Tumors. Clin Oncol. 2022;7:1965..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Cardiovascular Screening and Prevention in Female Breast Cancer Patients Receiving Radiotherapy
 Abstract  PDF  Full Text
Percutaneous Cryoablation for Clinical Stage I Non-Small Cell Lung Cancer: Histology, Results, and Safety
 Abstract  PDF  Full Text
View More...